S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
This Is Why Daktronics Fell 40% In One Day 
On the money: Yellen's next milestone is name on US currency
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Biden releasing nearly $36B to aid pensions of union workers
Is It Time To Throw In The Towel On Gamestop?
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Thursday 12/8/2022
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
This Is Why Daktronics Fell 40% In One Day 
On the money: Yellen's next milestone is name on US currency
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Biden releasing nearly $36B to aid pensions of union workers
Is It Time To Throw In The Towel On Gamestop?
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Thursday 12/8/2022
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
This Is Why Daktronics Fell 40% In One Day 
On the money: Yellen's next milestone is name on US currency
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Biden releasing nearly $36B to aid pensions of union workers
Is It Time To Throw In The Towel On Gamestop?
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Thursday 12/8/2022
S&P 500   3,963.51
DOW   33,781.48
QQQ   283.85
101 Christmas Gift Ideas Under $40
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
This Is Why Daktronics Fell 40% In One Day 
On the money: Yellen's next milestone is name on US currency
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Biden releasing nearly $36B to aid pensions of union workers
Is It Time To Throw In The Towel On Gamestop?
Will This Simple Tool Dominate 2023 Markets? (Ad)pixel
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Thursday 12/8/2022
NASDAQ:OVID

Ovid Therapeutics - OVID Stock Forecast, Price & News

$1.82
+0.07 (+4.00%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.76
$1.85
50-Day Range
$1.44
$1.89
52-Week Range
$1.41
$3.55
Volume
81,099 shs
Average Volume
149,853 shs
Market Capitalization
$128.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

Ovid Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
37.4% Upside
$2.50 Price Target
Short Interest
Healthy
0.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$37,290 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.79) to ($0.78) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

277th out of 1,022 stocks

Pharmaceutical Preparations Industry

113th out of 499 stocks

OVID stock logo

About Ovid Therapeutics (NASDAQ:OVID) Stock

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Receive OVID Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OVID Stock News Headlines

REAL,COMM and OVID among after hour movers
Ovid Therapeutics: Q1 Earnings Insights
Ovid Therapeutics GAAP EPS of -$0.38 misses by $0.22
See More Headlines
Receive OVID Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OVID Company Calendar

Last Earnings
11/08/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/21/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OVID
Fax
N/A
Employees
57
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.50
High Stock Price Forecast
$2.50
Low Stock Price Forecast
$2.50
Forecasted Upside/Downside
+37.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$122.83 million
Pretax Margin
-4,736.61%

Debt

Sales & Book Value

Annual Sales
$208.38 million
Cash Flow
$1.82 per share
Book Value
$2.64 per share

Miscellaneous

Free Float
62,927,000
Market Cap
$128.25 million
Optionable
Not Optionable
Beta
1.05

Key Executives

  • Dr. Jeremy Max Levin Ba Zoology (Age 69)
    Dphil, Mb Bchir, Pres, CEO & Chairman
    Comp: $847.07k
  • Mr. Jeffrey A. Rona (Age 54)
    Principal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer
    Comp: $613.18k
  • Mr. Thomas Michael Perone J.D. (Age 57)
    M.B.A., Gen. Counsel, Chief Compliance Officer & Corp. Sec.
    Comp: $632.11k
  • Dr. Matthew J. During DSc (Age 65)
    FACP, FRACP, M.D., Ph.D., Founder & Member of Scientific Advisory Board
  • Mr. Jason Tardio M.B.A. (Age 45)
    Chief Operating Officer
  • Ms. Lora Pike
    Sr. Director of Investor Relations & PR
  • Mr. Simon D. Kelner (Age 49)
    Sr. VP & Chief HR Officer
  • Dr. Dirk Haasner (Age 57)
    Sr. VP of Global Manufacturing & CMC QA
  • Ms. Suzanne K. Wakamoto SHRM-SCP
    SPHR, Sr. VP of Culture & Facilities
  • Dr. Claude Nicaise M.D. (Age 69)
    Head of R&D













OVID Stock - Frequently Asked Questions

Should I buy or sell Ovid Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OVID shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OVID, but not buy additional shares or sell existing shares.
View OVID analyst ratings
or view top-rated stocks.

What is Ovid Therapeutics' stock price forecast for 2023?

1 brokers have issued twelve-month target prices for Ovid Therapeutics' stock. Their OVID share price forecasts range from $2.50 to $2.50. On average, they predict the company's share price to reach $2.50 in the next year. This suggests a possible upside of 37.4% from the stock's current price.
View analysts price targets for OVID
or view top-rated stocks among Wall Street analysts.

How have OVID shares performed in 2022?

Ovid Therapeutics' stock was trading at $3.21 at the beginning of the year. Since then, OVID shares have decreased by 43.3% and is now trading at $1.82.
View the best growth stocks for 2022 here
.

When is Ovid Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our OVID earnings forecast
.

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics Inc. (NASDAQ:OVID) issued its earnings results on Tuesday, November, 8th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.04. The company had revenue of $0.01 million for the quarter.

What other stocks do shareholders of Ovid Therapeutics own?
When did Ovid Therapeutics IPO?

(OVID) raised $80 million in an initial public offering on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

What is Ovid Therapeutics' stock symbol?

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Who are Ovid Therapeutics' major shareholders?

Ovid Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Rubric Capital Management LP (6.41%), Vanguard Group Inc. (3.66%), Stonepine Capital Management LLC (2.19%), BlackRock Inc. (1.64%), Dimensional Fund Advisors LP (0.06%) and Tower Research Capital LLC TRC (0.05%). Insiders that own company stock include Amit Rakhit, Jason Tardio and Jeremy M Levin.
View institutional ownership trends
.

How do I buy shares of Ovid Therapeutics?

Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ovid Therapeutics' stock price today?

One share of OVID stock can currently be purchased for approximately $1.82.

How much money does Ovid Therapeutics make?

Ovid Therapeutics (NASDAQ:OVID) has a market capitalization of $128.25 million and generates $208.38 million in revenue each year. The company earns $122.83 million in net income (profit) each year or ($0.99) on an earnings per share basis.

How can I contact Ovid Therapeutics?

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The official website for the company is www.ovidrx.com. The company can be reached via phone at (646) 661-7661 or via email at investors@ovidrx.com.

This page (NASDAQ:OVID) was last updated on 12/9/2022 by MarketBeat.com Staff